CommercialPrior AuthMedium impact
08.01.10k, Octreotide Acetate (Sandostatin® LAR Depot)
Independence Blue Cross·Endocrinology, Gastroenterology, Oncology·Pharmacy
Effective date
Aug 18, 2025
We identified it
Jun 19, 2026
Summary
Independence Blue Cross updated their policy for Octreotide Acetate (Sandostatin LAR Depot) with changes to medical necessity criteria and medical coding requirements. This affects both the coverage determination process and billing procedures for this specialty pharmacy medication.
Action Required
By August 18, 2025: Billing team must review updated medical necessity criteria for Octreotide Acetate (Sandostatin LAR Depot) and verify any new coding requirements. Update prior authorization workflows and ensure documentation meets new medical necessity standards. Contact Independence Blue Cross or review full policy details for specific coding changes.